Future Prescriber最新文献

Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd.

Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley & Sons, Ltd.

Dexmedetomidine is a sedating agent with a pharmacological and therapeutic profile that is unlike those of the most commonly used sedative agents (midazolam and propofol). In this article, we provide an over view of dexmedetomidine in terms of its pharmacokinetics and pharmacodynamics, and describe its place in the management of patients in intensive care. Copyright © 2013 John Wiley & Sons, Ltd.

Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.

Prescribing medicines safely and effectively represents one of the greatest challenges for healthcare systems. Prescribing errors are common. A recent prospective observational study in the UK suggested that 10% of hospital prescriptions contained errors and that senior doctors were almost as frequently culpable as those who had recently graduated.¹ Copyright © 2012 John Wiley & Sons, Ltd.

Lipid-lowering is established as proven intervention to reduce atherosclerosis. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipo protein cholesterol (LDL-C), eg antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, eg novel peroxisomal proliferator activating receptors (PPAR) agonists, MTPIs; HDL: delipidation strategies and cholesterol ester transfer protein inhibitors (CETPIs) and modulators of inflammation, eg phospholipase inhibitors. Copyright © 2012 John Wiley & Sons, Ltd.

On 9 December 1969, in an open letter to President Nixon published in the Washington Post, Dr Sidney Farber, past president of the American Cancer Society was quoted as saying: ‘We are so close to a cure for cancer’.¹ So what happened? Copyright © 2012 John Wiley & Sons, Ltd.

Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.

A wide range of new targets in the management of pain were discussed by clinician and industry specialists at the Visiongain Annual Pain Management conference in July

Injection has long since been a barrier to insulin use. However, previous attempts to produce an inhaled insulin have met with difficulty. Technosphere insulin is a new system for delivery of inhaled insulin and is currently under review by the FDA. In this Drug profile, the authors discuss the technology and review the clinical data relating to its efficacy and adverse effects. Copyright © 2012 John Wiley & Sons, Ltd.